DxTerity Diagnostics’s REDI-Dx Wins 2013 NCT Cbrne Product Of The Year Award

LOS ANGELES--(BUSINESS WIRE)--DxTerity Diagnostics announced that REDI-Dx™, the company’s blood-based gene expression test for estimating individualized levels of radiation exposure,* was named the 2013 NCT CBRNe Product of the Year. The award was presented at the NCT CBRNe (Non-Conventional Threat Chemical Biological Radiological Nuclear explosion) Asia conference in Kuala Lumpur, Malaysia. REDI-Dx was unanimously selected by the contest jury because “it has a clear end-user benefit, economic efficiency and an excellent match between requirements and the offered solution,” according to Ilja Bonsen, founder and Managing Director of IB Consultancy, an independent defense and security firm specializing in non-conventional threats. “Against the background of mass scale incidents like Fukushima, it permits fast analysis and treatment of victims on the basis of low-cost testing,” according to several members of the award committee.

Help employers find you! Check out all the jobs and post your resume.